- Home
- HKPD vs BLRX Comparison
HKPD vs BLRX Comparison
Compare HKPD & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- BLRX
- Stock Information
- Founded
- HKPD 2016
- BLRX 2003
- Country
- HKPD Hong Kong
- BLRX Israel
- Employees
- HKPD N/A
- BLRX N/A
- Industry
- HKPD Other Pharmaceuticals
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- HKPD Health Care
- BLRX Health Care
- Exchange
- HKPD Nasdaq
- BLRX Nasdaq
- Market Cap
- HKPD 20.9M
- BLRX 17.1M
- IPO Year
- HKPD 2025
- BLRX 2011
- Fundamental
- Price
- HKPD $1.34
- BLRX $4.27
- Analyst Decision
- HKPD
- BLRX Strong Buy
- Analyst Count
- HKPD 0
- BLRX 2
- Target Price
- HKPD N/A
- BLRX $19.00
- AVG Volume (30 Days)
- HKPD 333.5K
- BLRX 54.8K
- Earning Date
- HKPD 08-14-2025
- BLRX 11-24-2025
- Dividend Yield
- HKPD N/A
- BLRX N/A
- EPS Growth
- HKPD N/A
- BLRX N/A
- EPS
- HKPD N/A
- BLRX N/A
- Revenue
- HKPD $20,313,818.00
- BLRX $17,251,000.00
- Revenue This Year
- HKPD N/A
- BLRX N/A
- Revenue Next Year
- HKPD N/A
- BLRX N/A
- P/E Ratio
- HKPD N/A
- BLRX N/A
- Revenue Growth
- HKPD 21.72
- BLRX 1.19
- 52 Week Low
- HKPD $0.81
- BLRX $2.30
- 52 Week High
- HKPD $3.79
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- HKPD 48.60
- BLRX 63.78
- Support Level
- HKPD $1.51
- BLRX $3.57
- Resistance Level
- HKPD $1.52
- BLRX $4.12
- Average True Range (ATR)
- HKPD 0.15
- BLRX 0.25
- MACD
- HKPD -0.02
- BLRX 0.04
- Stochastic Oscillator
- HKPD 23.81
- BLRX 92.31
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.